Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background Multiple sclerosis is an inflammatory disease of the central nervous system that destroys myelin, oligodendrocytes, and axons. Since most of the lesions of multiple sclerosis are not remyelinated, enhancement of remyelination is a possible therapeutic strategy that could perhaps be achieved with the transplantation of oligodendrocyte-producing cells into the lesions. We investigated the frequency distribution and configuration of oligodendrocytes in chronic lesions of multiple sclerosis to determine whether these factors limit remyelination. Methods Forty-eight chronic lesions obtained at autopsy from 10 patients with multiple sclerosis were examined immunocytochemically for oligodendrocytes and oligodendrocyte progenitor cells. Using confocal microscopy, we examined the three-dimensional relations between axons and the processes of premyelinating oligodendrocytes. Results Thirty-four of the 48 chronic lesions of multiple sclerosis contained oligodendrocytes with multiple extended processes that associated with demyelinated axons but failed to myelinate them. These axons were dystrophic and contained multiple swellings. In some regions, the densities of premyelinating oligodendrocytes (25 per square millimeter of tissue) were similar to those in the developing rodent brain (23 per square millimeter). In the patients with disease of long duration (more than 20 years), there were fewer lesions with premyelinating oligodendrocytes (P Conclusions Premyelinating oligode…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The efficacy of remyelination has been shown to depend on multiple factors such as, age, disease duration and lesion location.”
From BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis (2025) · cites this paper as [12]
In the citing paper
“The long‐term consequence of demyelination in the CNS is axonal damage and neurodegeneration (Chang et al. 2002) in both white and gray matter lesions, leading to progressive disease.”
From Depletion of Microglia Increases Cortical Oligodendrocyte Density During Remyelination (2026) · cites this paper as Chang et al. 2002
In the citing paper
“In MS lesions, OPCs are recruited but fail to differentiate into myelinating OLs, suggesting that remyelination is blocked at the differentiation and remyelination stage rather than during OPC recruitment (Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Chang et al., 2002
In the citing paper
“In MS lesions, OPCs are recruited but fail to differentiate into myelinating OLs, suggesting that remyelination is blocked at the differentiation and remyelination stage rather than during OPC recruitment (Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 1998).”
From miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS (2017) · cites this paper as Chang et al., 2002
In the citing paper
“Furthermore, oligodendrocyte progenitor cells (OPCs) are a population of adult stem cells responsible for mediating CNS myelin repair in demyelinating conditions such as MS [113,114].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [114]
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Self-citationNoseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Raff, M. C., Miller, R. H., & Noble, M. (1983) · Nature · doi:10.1038/303390a0 · Cited by 2,030
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
Cell death and control of cell survival in the oligodendrocyte lineage
Barres, B. A., Hart, I. K., Coles, H. S. R., Burne, J. F., Voyvodic, J. T., Richardson, W. D., & Raff, M. C. (1992) · Cell · doi:10.1016/0092-8674(92)90531-g · Cited by 1,345
Multiple Sclerosis and Chronic Autoimmune Encephalomyelitis
Kornek, B., Storch, M. K., Weissert, R., Wallstroem, E., Stefferl, A., Olsson, T., Linington, C., Schmidbauer, M., & Lassmann, H. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64537-3 · Cited by 921
The oligodendrocyte and its many cellular processes
PFEIFFER, S., WARRINGTON, A., & BANSAL, R. (1993) · Trends in Cell Biology · doi:10.1016/0962-8924(93)90213-k · Cited by 737
NG2-Positive Oligodendrocyte Progenitor Cells in Adult Human Brain and Multiple Sclerosis Lesions
Chang, A., Nishiyama, A., Peterson, J., Prineas, J., & Trapp, B. D. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-17-06404.2000 · Cited by 712
Self-citation
Research works printed but not linked: 2
- 10.1056/nejm199801293380610 · doi:10.1056/nejm199801293380610 · Paper page
- Prineas JW, 1989, Lab Invest, 61, 489
Cited by
Items 201–300 of 1,000
Nakahara, J., Kanekura, K., Nawa, M., Aiso, S., & Suzuki, N. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35440 · Cited by 102
Platelet-Derived Growth Factor Promotes Repair of Chronically Demyelinated White Matter
Vana, A. C., Flint, N. C., Harwood, N. E., Le, T. Q., Fruttiger, M., & Armstrong, R. C. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181587d46 · Cited by 101
“Immature oligodendrocyte lineage cells can persist in MS lesions (6, 7, 12, 47).”
BackgroundHuman endogenous retrovirus W in brain lesions: Rationale for targeted therapy in multiple sclerosis
van Horssen, J., van der Pol, S. M. A., Nijland, P. G., Amor, S., & Perron, H. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.04.006 · Cited by 103
LINGO-1 and its role in CNS repair
Mi, S., Sandrock, A. W., & Miller, R. H. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.03.018 · Cited by 108
NG2‐positive cells generate A2B5‐positive oligodendrocyte precursor cells
Baracskay, K. L., Kidd, G. J., Miller, R. H., & Trapp, B. D. (2007) · Glia · doi:10.1002/glia.20519 · Cited by 107
“NG2þ cells are also present in demyelinated lesions in multiple sclerosis brains (Chang et al., 2000) where their presence has been associated with the generation of new oligodendrocytes (Chang et al., 2002).”
BackgroundSelf-citationPremyelinating Oligodendrocytes: Mechanisms Underlying Cell Survival and Integration
Hughes, E. G., & Stockton, M. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.714169 · Cited by 98
Functional recovery of callosal axons following demyelination: A critical window
Crawford, D. K., Mangiardi, M., Xia, X., López-Valdés, H. E., & Tiwari-Woodruff, S. K. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.09.069 · Cited by 97
Chamberlain, K. A., Nanescu, S. E., Psachoulia, K., & Huang, J. K. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.010 · Cited by 87
“Semaphorin Signaling: Failure of OPCs to migrate into demyelinated lesions may contribute to failed remyelination in approximately 30% of MS lesions which exhibit reduced OPC numbers (Chang et al., 2002; Lucchinetti et al., 1999).”
BackgroundInfluentialDai, X., Chen, J., Xu, F., Zhao, J., Cai, W., Sun, Z., Hitchens, T. K., Foley, L. M., Leak, R. K., Chen, J., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19830791 · Cited by 97
Polarization of macrophages and microglia in inflammatory demyelination
Cao, L., & He, C. (2013) · Neuroscience Bulletin · doi:10.1007/s12264-013-1324-0 · Cited by 104
“However, although they are associated with demyelinated axons, they fail to myelinate them([43,44]) (Fig.”
BackgroundInhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis
Juryńczyk, M., Jurewicz, A., Bielecki, B., Raine, C. S., & Selmaj, K. W. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.10.013 · Cited by 98
“It is now well known that loss of oligodendrocytes (OLs) does not fully explain the limited amount of myelin repair as MS lesions contain considerable numbers of OL precursor cells (OPC) (Wolswijk, 1998; Chang et al., 2002).”
BackgroundOwens, T. (2003) · Current Opinion in Neurology · doi:10.1097/00019052-200306000-00003 · Cited by 94
Boulanger, J. J., & Messier, C. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.03.063 · Cited by 108
“…OPCs and premyelinating oligodendrocytes can be found in proximity of demyelinated axons in chronic MS lesions (Wolswijk, 1998, Chang et al., 2000, Chang et al., 2002, Reynolds et al., 2002, Kuhlmann et al., 2008, Sloane et al., 2010), these cells appear to be unable to differentiate into mature…”
InfluentialPushing Forward: Remyelination as the New Frontier in CNS Diseases
Kremer, D., Göttle, P., Hartung, H., & Küry, P. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.02.004 · Cited by 101
“As OPCs have been detected in chronic MS lesions even after years of disease progression [26], other determinants such as factors affecting migration and differentiation must be responsible for repair failure.”
BackgroundWeider, M., Starost, L. J., Groll, K., Küspert, M., Sock, E., Wedel, M., Fröb, F., Schmitt, C., Baroti, T., Hartwig, A. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03336-3 · Cited by 84
Aktaş, O., Kieseier, B. C., & Hartung, H. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2009.12.002 · Cited by 102
Giusto, E., Donegà, M., Cossetti, C., & Pluchino, S. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.03.009 · Cited by 100
“Most of the demyelinated regions undergo partial remyelination and show structural repair and recovery of function (Barkhof et al., 2003; Chang et al., 2002; Compston, 1996, 1997; Prineas et al., 1993; Raine and Wu, 1993).”
BackgroundOlesoxime accelerates myelination and promotes repair in models of demyelination
Magalon, K., Zimmer, C., Cayre, M., Khaldi, J., Bourbon, C., Robles, I., Tardif, G., Viola, A., Pruss, R. M., Bordet, T., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22593 · Cited by 93
Stacpoole, S. R. L., Spitzer, S., Bilican, B., Compston, A., Karadottir, R., Chandran, S., & Franklin, R. J. M. (2013) · Stem Cell Reports · doi:10.1016/j.stemcr.2013.09.006 · Cited by 88
FABP7 expression in normal and stab-injured brain cortex and its role in astrocyte proliferation
Sharifi, K., Morihiro, Y., Maekawa, M., Yasumoto, Y., Hoshi, H., Adachi, Y., Sawada, T., Tokuda, N., Kondo, H., Yoshikawa, T., et al. (2011) · Histochemistry and Cell Biology · doi:10.1007/s00418-011-0865-4 · Cited by 90
“the pathophysiology of demyelinating disorders such as multiple sclerosis (Chang et al. 2002; Kuhlmann et al. 2008).”
BackgroundBlack, J. A., Waxman, S. G., & Smith, K. J. (2006) · Brain · doi:10.1093/brain/awl057 · Cited by 102
“Demyelinated axons can be repaired by remyelination in both humans (Prineas et al., 1993; Chang et al., 2002) and animals.”
BackgroundThe pathophysiological role of astrocytic endothelin-1
Hostenbach, S., D’haeseleer, M., Kooijman, R., & Keyser, J. D. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.009 · Cited by 96
The active contribution of OPCs to neuroinflammation is mediated by LRP1
Fernández-Castañeda, A., Chappell, M. S., Rosen, D. A., Seki, S. M., Beiter, R. M., Johanson, D. M., Liskey, D., Farber, E., Onengut-Gumuscu, S., Overall, C. C., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-019-02073-1 · Cited by 90
Effectors of Demyelination and Remyelination in the CNS: Implications for Multiple Sclerosis
Rodriguez, M. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00065.x · Cited by 87
“In addition, experiments have demonstrated that 34 out of 48 lesions contain oligodendrocytes with multiple extended processes associated with demyelinated axons but fail to myelinate them (19).”
BackgroundPromoting Remyelination in Multiple Sclerosis—Recent Advances
Jolanda Münzel, E., & Williams, A. (2013) · Drugs · doi:10.1007/s40265-013-0146-8 · Cited by 83
“Around 70 % of demyelinated MS lesions contain immature oligodendroglial cells that appear to be in an arrested state, unable to fully differentiate [3, 90].”
BackgroundRegulation of remyelination in multiple sclerosis
Hanafy, K. A., & Sloane, J. A. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.048 · Cited by 86
“ber of associated internodes in MS lesions [21].”
BackgroundLee, H. K., Chaboub, L. S., Zhu, W., Zollinger, D., Rasband, M. N., Fancy, S. P. J., & Deneen, B. (2015) · Neuron · doi:10.1016/j.neuron.2015.02.024 · Cited by 87
ZFP191 is required by oligodendrocytes for CNS myelination
Howng, S. Y. B., Avila, R. L., Emery, B., Traka, M., Lin, W., Watkins, T., Cook, S., Bronson, R., Davisson, M., Barres, B. A., et al. (2010) · Genes & Development · doi:10.1101/gad.1864510 · Cited by 83
“Interestingly, oligodendrocytes apparently blocked at late stages of maturation, similar to that observed in the Zfp191 mutants, can be seen in the vicinity of demyelinated axons in MS patients that display remyelination failure (Chang et al. 2002; Kuhlmann et al. 2008).”
BackgroundDiet-dependent regulation of TGFβ impairs reparative innate immune responses after demyelination
Bosch-Queralt, M., Cantuti-Castelvetri, L., Damkou, A., Schifferer, M., Schlepckow, K., Alexopoulos, I., Lütjohann, D., Klose, C., Vaculčiaková, L., Masuda, T., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00341-7 · Cited by 88
Remyelination Therapy in Multiple Sclerosis
Harlow, D. E., Honce, J. M., & Miravalle, A. A. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00257 · Cited by 82
Gap junction pathology in multiple sclerosis lesions and normal-appearing white matter
Markoullis, K., Sargiannidou, I., Schiza, N., Hadjisavvas, A., Roncaroli, F., Reynolds, R., & Kleopa, K. A. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0978-4 · Cited by 91
Miyamoto, N., Tanaka, R., Shimura, H., Watanabe, T., Mori, H., Onodera, M., Mochizuki, H., Hattori, N., & Urabe, T. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.210 · Cited by 86
“…in which remyelination eventually fails; those in which OPCs are present in insufficient numbers, implying failure of survival or recruitment (Niehaus et al, 2000; Prineas et al, 1993), and those in which OPCs are present but are unable to complete myelination (Chang et al, 2002; Wolswijk, 1998).”
BackgroundLiu, Z., Yan, M., Liang, Y., Liu, M., Zhang, K., Shao, D., Jiang, R., Li, L., Wang, C., Nussenzveig, D. R., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.018 · Cited by 89
Multiple sclerosis: Neuroprotective alliance of estrogen–progesterone and gender
Kipp, M., Amor, S., Krauth, R., & Beyer, C. (2012) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2012.01.001 · Cited by 91
Vallée, A., Vallée, J.-N., Guillevin, R., & Lecarpentier, Y. (2017) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0550-9 · Cited by 93
“In white matter lesions of MS, oligodendrocyte precursor cells (OPC) show a stop state and cannot differentiate into myelinating OLs (Chang et al. 2002; Billiards et al. 2008; Kuhlmann et al. 2008; Fancy et al. 2010; Buser et al. 2012; Back and Rosenberg 2014).”
BackgroundInfluentialHooijmans, C. R., Hlavica, M., Schuler, F. A. F., Good, N., Good, A., Baumgartner, L., Galeno, G., Schneider, M. P., Jung, T., de Vries, R., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-35734-4 · Cited by 72
Lachapelle, F., Avellana‐Adalid, V., Nait‐Oumesmar, B., & Evercooren, A. B.-V. (2002) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2002.1124 · Cited by 92
Contrasting effects of mitogenic growth factors on myelination in neuron–oligodendrocyte co‐cultures
Wang, Z., Colognato, H., & ffrench‐Constant, C. (2007) · Glia · doi:10.1002/glia.20480 · Cited by 81
“The identity of these mechanisms is important, as they may reveal why oligodendrocytes in MS lesions reach the premyelinating stage (as with the PDGF-treated cells in our experiments) but are then unable to repair the lesion (Chang et al., 2002; Wolswijk, 1998).”
Activation of CXCR7 receptor promotes oligodendroglial cell maturation
Göttle, P., Kremer, D., Jander, S., Ödemis, V., Engele, J., Hartung, H., & Küry, P. (2010) · Annals of Neurology · doi:10.1002/ana.22214 · Cited by 88
“Inefficient CNS remyelination observed in neuroinflammatory demyelinating diseases such as MS is thought to be mainly due to the limited ability of resident precursor cells to differentiate properly.(5,6) With this study, we demonstrate that activation of the chemokine receptor CXCR7 leads to Erk phosphorylation and t…”
BackgroundBisphenol A Exerts Thyroid-Hormone-Like Effects on Mouse Oligodendrocyte Precursor Cells
Seiwa, C., Nakahara, J., Komiyama, T., Katsu, Y., Iguchi, T., & Asou, H. (2004) · Neuroendocrinology · doi:10.1159/000080663 · Cited by 81
Hyaluronan Synthesis, Catabolism, and Signaling in Neurodegenerative Diseases
Sherman, L. S., Matsumoto, S. G., Su, W., Srivastava, T., & Back, S. A. (2015) · International Journal of Cell Biology · doi:10.1155/2015/368584 · Cited by 91
Targeting TrkB with a Brain-Derived Neurotrophic Factor Mimetic Promotes Myelin Repair in the Brain
Fletcher, J. L., Wood, R. J., Nguyen, J., Norman, E. M. L., Jun, C. M. K., Prawdiuk, A. R., Biemond, M., Nguyen, H. T. H., Northfield, S. E., Hughes, R. A., et al. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.0487-18.2018 · Cited by 81
“These abilities are essential to a remyelinating strategy, particularly for MS where OPC differentiation appears arrested (Chang et al., 2002).”
BackgroundInfluentialKipp, M., Gingele, S., Pott, F., Clarner, T., van der Valk, P., Denecke, B., Gan, L., Siffrin, V., Zipp, F., Dreher, W., et al. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.05.003 · Cited by 83
“In some lesions, however, progenitor cells are present (Scolding et al., 1998; Chang et al., 2000, 2002; Wolswijk, 1998), but remyelination still fails either because axons are not permissive for remyelination (Charles et al., 2002) or the maturation of progenitor cells is inhibited (John et al.,…”
Cortical remyelination is heterogeneous in multiple sclerosis
Strijbis, E. M. M., Kooi, E.-J., van der Valk, P., & Geurts, J. J. G. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx023 · Cited by 82
Valerio, A., Ferrario, M., Dréano, M., Garotta, G., Spano, P., & Pizzi, M. (2002) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2002.1208 · Cited by 91
“Despite detection of OPCs and premyelinating oligodendrocytes also in chronic lesions of human MS with densities similar to those of developing rodent brain, remyelination appears to be limited, possibly due to an imbalance of growth factors that regulate myelination (Chang et al., 2002).”
BackgroundPromoting remyelination in multiple sclerosis: Current drugs and future prospects
Kremer, D., Küry, P., & Dutta, R. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458514566419 · Cited by 76
Höftberger, R., Fink, S., Aboul‐Enein, F., Botond, G., Olah, J., Berki, T., Ovadi, J., Lassmann, H., Budka, H., & Kovacs, G. G. (2010) · Glia · doi:10.1002/glia.21054 · Cited by 79
“…include a depletion of the OPC pool due to repeated de- and remyelination processes (Keirstead et al., 1998), impaired differentiation and migration of precursor cells into lesion areas (Kuhlmann et al., 2008), or due to a disturbed microenvironment within the lesions (Chang et al., 2002).”
BackgroundInfluentialStarost, L., Lindner, M., Herold, M., Xu, Y. K. T., Drexler, H. C. A., Heß, K., Ehrlich, M., Ottoboni, L., Ruffini, F., Stehling, M., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02217-8 · Cited by 79
Simkins, T., Duncan, G. J., & BOURDETTE, D. N. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-021-01110-5 · Cited by 82
Inhibitors of myelination: ECM changes, CSPGs and PTPs
Harlow, D. E., & Macklin, W. B. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2013.10.017 · Cited by 78
“It is unlikely that this inability to remyelinate results from an absence of OPCs in the adult CNS, as OPCs are present in elderly patients even after decades of disease (Chang et al., 2002, 2012).”
Multiple Sclerosis: New Insights in Pathogenesis and Novel Therapeutics
Ontaneda, D., Hyland, M. H., & Cohen, J. A. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-042910-135833 · Cited by 96
Xiao, L., Guo, D., Hu, C., Shen, W., Shan, L., Li, C., Liu, X., Yang, W., Zhang, W., & He, C. (2012) · Glia · doi:10.1002/glia.22333 · Cited by 74
“As considerable amount of OPCs have been found to be present in chronic demyelinated MS lesions (Chang et al., 2002; Wolswijk, 1998), it is highly suggested that the remyelination failure might be resulted from the inability of these immature progenitor cells of the oligodendrocyte lineage to differentiate into their…”
BackgroundPerturbed Myelination Process of Premyelinating Oligodendrocyte in Niemann-PickType C Mouse
Takikita, S., Fukuda, T., Mohri, I., Yagi, T., & Suzuki, K. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.6.660 · Cited by 79
“The presence of premyelinating OLs (42) and axonal abnormality with increased APP immunoreactivity (43, 44) in MS were also reported, and the authors suggested axonal involvement in failure of remyelination.”
BackgroundContrasting somatic mutation patterns in aging human neurons and oligodendrocytes
Ganz, J., Luquette, L. J., Bizzotto, S., Miller, M. B., Zhou, Z., Bohrson, C. L., Jin, H., Tran, A. V., Viswanadham, V., McDonough, G. A., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.025 · Cited by 88
“27,28 29-32 Unlike neurons, which mostly arise before birth, OLs are replenished throughout postnatal life by resident OL-precursor cells (OPCs), 29,33 with the rate of replenishment diminishing with age.”
Measuring longitudinal myelin water fraction in new multiple sclerosis lesions
Vargas, W. S., Monohan, E., Pandya, S., Raj, A., Vartanian, T. K., Nguyen, T. D., Rúa, S. M. H., & Gauthier, S. A. (2015) · NeuroImage Clinical · doi:10.1016/j.nicl.2015.09.003 · Cited by 79
“This is an open access article under however given the presence of oligodendrocyte progenitor cells in brains ofmultiple sclerosis patients (Chang et al., 2002) stimulation of these cells to enhance endogenous remyelination is considered the next frontier in therapeutic advancement for multiple sclerosis.”
Zebrafish myelination: a transparent model for remyelination?
Buckley, C. E., Goldsmith, P., & Franklin, R. J. M. (2008) · Disease Models & Mechanisms · doi:10.1242/dmm.001248 · Cited by 72
“This conclusion mirrors clinical findings, where it is common to see MS plaques containing OPCs with no evidence of remyelination (Chang et al., 2000; Chang et al., 2002; Kuhlmann et al., 2008; Wolswijk, 2002).”
ResultLINGO-1 antagonists as therapy for multiple sclerosis:in vitroandin vivoevidence
Rudick, R. A., Mi, S., & Sandrock, A. W. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.10.1561 · Cited by 85
“Despite the close proximity between premyelinating oligodendrocytes and demyelinated axons observed in chronic MS lesions, remyelination of these axons failed, suggesting that inhibitory factors in the lesion environment prevent remyelination [26] .”
BackgroundSelf-citationTemporal dynamics of myelination in the zebrafish spinal cord
Buckley, C. E., Marguerie, A., Alderton, W. K., & Franklin, R. J. M. (2010) · Glia · doi:10.1002/glia.20964 · Cited by 76
“Therefore, unlike transgenic lines, this allows myelin to be distinguished from the processes of process-bearing oligodendrocytes that have not actually produced myelin, such as are sometimes seen in MS lesions (Chang et al., 2002).”
BackgroundAdaptive human immunity drives remyelination in a mouse model of demyelination
El Behi, M., Sanson, C., Bachelin, C., Guillot-Noël, L., Fransson, J., Stankoff, B., Maillart, E., Sarrazin, N., Guillemot, V., Abdi, H., et al. (2017) · Brain · doi:10.1093/brain/awx008 · Cited by 67
“In the last decade, the cause of the failure of remyelination in some patients has been debated: whether it results from a defect of OPC recruitment (Wolswijk, 2002; Boyd et al., 2013), a decrease of OPC differentiation (Chang et al., 2002), or both (Sim et al., 2002).”
BackgroundHamaguchi, M., Muramatsu, R., Fujimura, H., Mochizuki, H., Kataoka, H., & Yamashita, T. (2019) · eLife · doi:10.7554/elife.41869 · Cited by 74
“Consistent with this, an area of chronic demyelination that fails to undergo remyelination is considered to arise due to the decline of maturation activity in oligodendrocytes (Chang et al., 2002; Wolswijk, 1998).”
BackgroundTalbott, J. F., Cao, Q., Bertram, J. P., Nkansah, M. K., Benton, R. L., Lavik, E., & Whittemore, S. R. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.12.013 · Cited by 84
Mechanisms of CNS remyelination—the key to therapeutic advances
Zhao, C., Fancy, S. P. J., Kotter, M., Li, W., & Franklin, R. J. M. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.03.008 · Cited by 88
“This conclusion has considerable resonance with the now well-recognised failure of OPC differentiation that occurs in a proportion of non-remyelinating chronic MS lesions [35–37].”
BackgroundPsenicka, M. W., Smith, B. C., Tinkey, R. A., & Williams, J. L. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.654284 · Cited by 75
“, 2019), a deficiency in the ability of OPCs to differentiate into OLs contributes to demyelination and axonal damage within lesions, leading to neurodegeneration (Chang et al., 2002; Boyd et al., 2013; Gruchot et al., 2019).”
BackgroundInfection with an Endemic Human Herpesvirus Disrupts Critical Glial Precursor Cell Properties
Dietrich, J., Blumberg, B. M., Roshal, M., Baker, J. V., Hurley, S. D., Mayer-Pröschel, M., & Mock, D. J. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.5584-03.2004 · Cited by 77
“Although normal numbers of OPCs are frequently present within early demyelinating lesions, cells within the precursor pool appear to remain quiescent and unable to appropriately proliferate and/or differentiate (Wolswijk, 1998; Chang et al., 2000, 2002 ).”
CXCR2 signaling protects oligodendrocyte progenitor cells from IFN-γ/CXCL10-mediated apoptosis
Tirotta, E., Ransohoff, R. M., & Lane, T. E. (2011) · Glia · doi:10.1002/glia.21195 · Cited by 71
“Failed remyelination by OPCs is a characteristic feature of MS and may be associated with impaired OPC function and/ or death of these cells (Chang et al., 2002).”
BackgroundThe Xenopus tadpole: An in vivo model to screen drugs favoring remyelination
Mannioui, A., Vauzanges, Q., Fini, J. B., Henriet, E., Sekizar, S., Azoyan, L., Thomas, J. L., Pasquier, D. D., Giovannangeli, C., Demeneix, B., et al. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458517721355 · Cited by 71
Histamine Receptor 3 negatively regulates oligodendrocyte differentiation and remyelination
Chen, Y., Zhen, W., Guo, T., Zhao, Y., Liu, A., Rubio, J. P., Krull, D., Richardson, J. C., Lu, H., & Wang, R. (2017) · PLOS ONE · doi:10.1371/journal.pone.0189380 · Cited by 71
Oligodendrocyte precursor cells as a therapeutic target for demyelinating diseases
Skaper, S. D. (2019) · Progress in Brain Research · doi:10.1016/bs.pbr.2019.03.013 · Cited by 71
Feliú, A., Moreno‐Martet, M., Mecha, M., Carrillo‐Salinas, F. J., de Lago, E., Fernández‐Ruiz, J., & Guaza, C. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13159 · Cited by 70
“In MS, repair and remyelination occur in shadow plaques (Chang et al., 2012) but, as the disease progresses, remyelination becomes less efficient (Chang et al., 2002; Franklin, 2002; Goldschmidt et al., 2009).”
BackgroundThe effects of blood–brain barrier disruption on glial cell function in multiple sclerosis
McQuaid, S., Cunnea, P., McMahon, J., & Fitzgerald, U. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370329 · Cited by 69
Garay, L. I., Deniselle, M. C. G., Brocca, M. E., Lima, A. E., Roig, P., & Nicola, A. F. D. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.032 · Cited by 78
“demyelination area and differentiation into myelin-forming oligodendrocytes (Chang et al., 2002; McDonald and Belegu, 2006; Franklin and Ffrench-Constant, 2008).”
Harnessing the integrated stress response for the treatment of multiple sclerosis
Way, S. W., & Popko, B. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00381-6 · Cited by 71
Feliú, A., Bonilla del Río, I., Carrillo-Salinas, F. J., Hernández-Torres, G., Mestre, L., Puente, N., Ortega-Gutiérrez, S., López-Rodríguez, M. L., Grandes, P., Mecha, M., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2900-16.2017 · Cited by 68
“, 2012); but as the disease progresses, remyelination becomes less efficient (Chang et al., 2002; Franklin, 2002; Goldschmidt et al., 2009) and the patients’ disability augments.”
BackgroundInhibition of oligodendrocyte precursor cell differentiation by myelin-associated proteins
Syed, Y. A., Baer, A. S., Lubec, G., Hoeger, H., Widhalm, G., & Kotter, M. R. (2008) · Neurosurgical Focus · doi:10.3171/foc/2008/24/3-4/e4 · Cited by 65
Regenerative Capacity of Macrophages for Remyelination
Rawji, K. S., Mishra, M. K., & Yong, V. W. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00047 · Cited by 66
Alexander, G. C., Kurlander, J. E., & Wynia, M. K. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.0233.x · Cited by 71
Maier, O., van der Heide, T., van Dam, A., Baron, W., de Vries, H., & Hoekstra, D. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.09.012 · Cited by 72
Ma, J., Tanaka, K. F., Shimizu, T., Bernard, C. C. A., Kakita, A., Takahashi, H., Pfeiffer, S. E., & Ikenaka, K. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22567 · Cited by 68
“The arrest of oligodendrocyte maturation has been thought of as an essential reason for remyelination impairment (Chang et al., 2002).”
Multiple sclerosis and anesthetic implications
Dorotta, I. R., & Schubert, A. (2002) · Current Opinion in Anaesthesiology · doi:10.1097/00001503-200206000-00015 · Cited by 70
Klotho protein in neurodegenerative disorders
Torbus, M., Bartman, W., & Adamczyk-Sowa, M. H. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3496-x · Cited by 67
Cell-based remyelinating therapies in multiple sclerosis: evidence from experimental studies
Pluchino, S., Furlan, R., & Martino, G. (2004) · Current Opinion in Neurology · doi:10.1097/00019052-200406000-00003 · Cited by 69
Kuboyama, K., Fujikawa, A., Suzuki, R., & Noda, M. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2127-15.2015 · Cited by 70
“Oligodendrocyte precursor cells (OPCs), the principal source of myelinating oligodendrocytes (Goldman et al., 2012), differentiate to myelinate demyelinated axons again (remyelination) during remitting stages (Chang et al., 2002).”
BackgroundPedraza, C. E., Monk, R. J., Lei, J., Hao, Q., & Macklin, W. B. (2008) · Glia · doi:10.1002/glia.20702 · Cited by 74
“In adults, oligodendrocyte precursors are present throughout the brain, they can migrate to damaged areas and to some extent remyeli- nate demyelinated lesions (Chang et al., 2000, 2002).”
BackgroundThe effect of CXCL1 on human fetal oligodendrocyte progenitor cells
Filipovic, R., & Zečević, N. (2007) · Glia · doi:10.1002/glia.20582 · Cited by 73
“This is supported by the finding that high concentrations of CXCL1 were observed locally around MS lesions (Filipovic et al, 2002, 2003), the site where attempts of remyelination were described (Chang et al., 2002; Franklin, 2002; Levine et al., 2001; Raine et al., 1981; Wolswijk, 1996).”
BackgroundWilliams, J. L., Patel, J. R., Daniels, B. P., & Klein, R. S. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131224 · Cited by 73
“Despite the presence of oligodendrocyte progenitor cells (OPCs) in MS lesions (Chang et al., 2000, 2002), remyelination gradually fails while demyelination continues, contributing to progressive clinical deterioration (Compston and Coles, 2002).”
BackgroundMyelin repair: the role of stem and precursor cells in multiple sclerosis
Chandran, S., Hunt, D. P. J., Joannides, A. J., Zhao, C., Compston, A., & Franklin, R. J. M. (2007) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2006.2019 · Cited by 73
“…to chronically demyelinated MS lesions (which often contain abundant quiescent oligodendrocyte lineage cells that fail to fully differentiate into remyelinating oligodendrocytes) for which remyelination enhancing therapies are required (Scolding et al. 1998; Wolswijk 1998; Chang et al. 2002).”
BackgroundSchepers, M., Paes, D., Tiane, A., Rombaut, B., Piccart, E., van Veggel, L., Gervois, P., Wolfs, E., Lambrichts, I., Brullo, C., et al. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2022.12.020 · Cited by 72
“The total protein concentrations were assessed using ABBREVIATIONS: MS = multiple sclerosis; SD = standard deviation; PMI = postmortem interval; PRMS = primary relapsing MS; SPMS = secondary progressive MS; PPMS = primary progressive MS; n.a. = not applicable.”
InfluentialTang, C. Y., Friedman, J., Shungu, D., Chang, L., Ernst, T., Stewart, D., Hajianpour, A., Carpenter, D., Ng, J., Mao, X., et al. (2007) · BMC Psychiatry · doi:10.1186/1471-244x-7-25 · Cited by 64
“O2-A progenitor cells are putatively involved with glia repair processes[71].”
BackgroundLindner, M., Thümmler, K., Arthur, A. T., Brunner, S. P., Elliott, C., McElroy, D., Mohan, H., Williams, A., Edgar, J. M., Schuh, C., et al. (2015) · Brain · doi:10.1093/brain/awv102 · Cited by 73
“…is associated with the appearance of multi-branched ‘pre-myelinating’ oligodendrocytes that extend processes that interact with axons, but fail to form myelin sheaths; an oligodendrocyte phenotype reminiscent of that seen in chronically demyelinated multiple sclerosis lesions (Chang et al., 2002).”
BackgroundMethodInfluentialWhite matter synapses: Form, function, and dysfunction
Alix, J. J. P., & Domingues, A. M. D. J. (2011) · Neurology · doi:10.1212/wnl.0b013e3182088273 · Cited by 72
Disease-Modifying Agents for Multiple Sclerosis: Recent Advances and Future Prospects
Menge, T., Weber, M. S., Hemmer, B., Kieseier, B. C., von Büdingen, H. ‐., Warnke, C., Zamvil, S. S., Boster, A. L., Khan, O., Hartung, H. P., et al. (2008) · Drugs · doi:10.2165/0003495-200868170-00004 · Cited by 72
Huang, H., Teng, P., Du, J., Meng, J., Hu, X., Tang, T., Zhang, Z., Qi, Y. B., & Qiu, M. S. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.0154-18.2018 · Cited by 69
“In spinal injuries and acute MS lesions, OPCs still exist but fail to differentiate effectively into myelinating oligodendrocytes (Raine and Wu, 1993; Wolswijk, 1998; Chang et al., 2002; Jennings and Carroll, 2010).”
BackgroundSeifert‐Held, T., Bauer, J., Weissert, R., Fazekas, F., & Storch, M. K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0170-9 · Cited by 69
“cells [6, 19, 20, 31, 41] or premyelinating oligodendrocytes [7] but these cells fail to diVerentiate into myelinating oligodendrocytes.”
BackgroundiPS-derived neural progenitor cells from PPMS patients reveal defect in myelin injury response
Nicaise, A. M., Banda, E., Guzzo, R. M., Russomanno, K., Castro-Borrero, W., Willis, C. M., Johnson, K. M., Lo, A. C., & Crocker, S. J. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2016.11.012 · Cited by 64
“This observation indicates an endogenous potential for NPCs as a source of limiting factors related to disease and/or the lesion microenvironment (Chang et al., 2002).”
BackgroundGalloway, D. A., Blandford, S. N., Berry, T., Williams, J. B., Stefanelli, M., Ploughman, M., & Moore, C. S. (2019) · Glia · doi:10.1002/glia.23576 · Cited by 64
Critical role for PAR1 in kallikrein 6‐mediated oligodendrogliopathy
Burda, J. E., Radulovic, M., Yoon, H., & Scarisbrick, I. A. (2013) · Glia · doi:10.1002/glia.22534 · Cited by 67
“OPCs, which hold the potential to differentiate and remyelinate axons, are prevalent at sites of white matter injury (Chang et al., 2002; Kuhlmann et al., 2008; Tripathi and McTigue, 2007; Wolswijk, 1998) although in many cases remyelination stalls due, in part, to a failure of OPC maturation.”
BackgroundRemyelination Therapy for Multiple Sclerosis
Keough, M. B., & Yong, V. W. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0152-7 · Cited by 74
““Premyelinating” oligodendrocytes, defined as being positive for the marker proteolipid protein 1 and extending processes, have also been reported in chronic MS lesions [54].”
BackgroundClarner, T., Parabucki, A., Beyer, C., & Kipp, M. (2011) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2011.02140.x · Cited by 59
Promoting repair in multiple sclerosis: problems and prospects
Lubetzki, C., Williams, A., & Stankoff, B. (2005) · Current Opinion in Neurology · doi:10.1097/01.wco.0000169739.83793.e0 · Cited by 63
Oligodendrocyte development in the embryonic brain: the contribution of the plp lineage
Le Bras, B., Chatzopoulou, E., Heydon, K., Martinez, S., Ikenaka, K., Prestoz, L., Spassky, N., Zalc, B., & Thomas, J.-L. (2005) · The International Journal of Developmental Biology · doi:10.1387/ijdb.041963bl · Cited by 62
“Finally, heterogeneity among OPCs has also been suggested in the adult brain by the presence of functional subpopulations of OPCs in MS lesions (Chang et al., 2002).”
Metadata
- Authors
- Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D.
- Affiliations
- Cleveland Clinic (US)
- VA West Los Angeles Medical Center (US)
- Cleveland Clinic Research (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-01-17
- Volume
- 346
- Issue
- 3
- Pages
- 165-173
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2058358434
- Cited by
- 991
- References
- 39
- Citations by year
- 2026: 19 · 2025: 25 · 2024: 42 · 2023: 38 · 2022: 32 · 2021: 34 · 2020: 36 · 2019: 57 · 2018: 43 · 2017: 52 · 2016: 44 · 2015: 55 · 2014: 44 · 2013: 50 · 2012: 40
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (R01 NS35058, P01NS038667, R01NS035058, P01-NS-38667)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- multiple sclerosis, remyelination, chronic lesions, demyelinated axons, oligodendrocyte precursor cells, disease duration
- MeSH terms
- Chondroitin Sulfate Proteoglycan 4, Adult, Aged, Antigens, Axons, Brain, Brain Chemistry, Female, Humans, Male, Middle Aged, Multiple Sclerosis, Nerve Fibers, Myelinated, Oligodendroglia, Proteoglycans, Stem Cells, Microscopy, Confocal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.